Scientific Program

Program subject to change

Monday, 2 July 2018




Welcome and Opening of the Congress


Session 1: Clinical Research in HIV
Chair: Alan Winston, Imperial College, London, UK


Cure for HIV - Overview and Future Studies in HIV Cure
John Frater,
 University of Oxford, UK
  • The aims of HIV cure research
  • Remission as a model for HIV cure
  • Future strategies for HIV cure and remission


HIV and Ageing - Overview of HIV Ageing
Caroline Sabin, 
University College London, UK

  • How has the epidemiology of HIV changed in the UK?
  • What clinical consequences are we seeing as the population of people living with HIV ages?
  • Is there evidence to support a pattern of premature ageing in people living with HIV?


HIV and Ageing - Frailty and HIV
Tom Levett


Cognitive Decline in HIV
Alan Winston, 
Imperial College London, UK

  • Cognitive disorders remain prevalent in otherwise effectively treated persons living with HIV
  • Lifestyle factors are likely an important contributing factor
  • Ongoing immune activation and neuro-inflammation are other pathogenic mechanisms which may be suitable mechanisms to target in future interventional studies.


Networking, Coffee Break and visit the Exhibition


Session 2:  Challenges in Sexual Health: diagnosis, treatment and prevention
Chair: Jonathan RossNIHR, UK


Point of Care Testing for Sexually Transmitted Infections – Where are we now and where do we want to be
Tariq Sadiq
St George's, University of London, UK

  • Novel Diagnostics promise to radically transform STI care and help tackle antibiotic resistance
  • Ongoing monitoring accuracy and clinical impact are required to ensure utility of these technologies
  • Regulatory changes are required to enable rapid adoption


Treating antibiotic resistant gonorrhoea – what are the gaps
Magnus Unemo
Örebro University Hospital, Sweden


Delivering digital technology to control the spread of sexually transmitted infections
Claudia Estcourt, 
Glasgow Caledonian University, UK

  • What is the potential for health gain using digital technologies within Sexual health care and what might be the unintended consequences / harms?
  • What types of digital interventions are we delivering now and does the evidence support them?
  • What might the future hold and what sort of research (and funding) is needed to maximise the utility of digital health in those at greatest risk of STIs & HIV?


Networking, Lunch Break and visit the Exhibition


Session 3:  Diagnostics Technologies
Chair: Mathew A Diggle, Nottingham University Hospitals, NHS, UK


POCT for Diagnostics
Andrew Kemp
Q Technologies Group, USA

  • New test methods for determining surface bio contamination levels.
  • New standards for cleaning, disinfection and testing surfaces in healthcare.
  • Standardisation of efficacy testing methods for regulatory bodies, academic institutions, and healthcare facilities.


Diabetic Infection and Microbiome Analysis
William Jeffcoate
Nottingham University Hospitals Trust, UK

  • In diabetic foot ulcers, both the diagnosis of infection and the diagnosis of remission are predominantly clinical and management is often supervised by clinicians without specialist skills
  • Broad spectrum antibiotics are almost certainly used too often and for too long in many cases.
  • There is an urgent need for well designed clinical trials to substantiate the use of antibiotics for both skin and soft tissue infection and osteomyelitis.


Molecular Point-of-care Testing for Influenza and Other Respiratory Viruses 
Tristan ClarkUniversity of Southampton, UK

  • Molecular POCT for influenza has the potential to improve patient care and NHS resource use
  • Recent high-quality evidence suggests that POCT improves patient outcomes, is safe and is cost effective
  • Models for the implementation of molecular POCT need to be explored and defined before it can be adopted nationally


 Networking, Coffee Break and visit the Exhibition


Session 4:  Diagnostics - Regulations and Trials
Chair: Tristan Clark, University of Southampton, UK


Regulatory issues in Infection Diagnostics
Erica Conway, BSI Medical Devices, UK


National Institute for Health and Care Excellence (NICE) and Evaluation of Infection Diagnostics
Rebecca Albrow, NICE, UK


POC Diagnostics for Blood-borne infection and the NIHR London In-vitro diagnostics Co-operative
Graham Cooke, Imperial College London, UK




Session 5: New developments in Antimicrobial Resistance
Chair: Effrossyni Gkrania-Klotsas, Addenbrooke’s Hospital, Cambridge, UK


Lab-on-Chip and Biosensor Technology Developments for Rapid Infectious Disease and AMR Diagnosis
Despina Moschou, University of Bath, UK

  • Lab-on-Chip technology
  • Devices and concepts for Rapid Infectious disease and AMR diagnosis on disposable chips
  • Current research at the University of Bath in LoC devices for Infectious disease diagnosis and management


Resistance Guided Therapy: Refining the Management of Mycoplasma Genitalium and Neisseria Gonorrhoeae
Litty Tan, Speedx, New South Wales, Australia

Tuesday, 3 July 2018




Session 6:  Clinical trials in Infection: Challenges and Solutions
Chair: Miruna David, University Hospitals Birmingham NHS Trust, UK


Challenges in Clinical Trials in Infection
Sarah Pett, 
Senior Clinical Lecturer in Infectious Diseases at the Medical Research Council Clinical Trials Unit and University College, London, UK

  • How international networks can be used to answer important strategic questions about the management of chronic infectious diseases 
  • Acute infections – using influenza as a model for some of the challenges 
  • Research capacity


The COMBACTE approach: using clinical research networks to deliver clinical trials in antimicrobial resistance
Marc Bonten, 
Head of the Department of Medical Microbiology at University Medical Center Utrecht and academic lead of the COMBACTE program, the Netherlands


Investigator-Led Clinical Trials in Infection
Tim Peto, UK




Networking, Coffee Break and visit the Exhibition


Session 7: National Institute for Health Research: supporting research in the NHS
Chair: Jane Minton, Leeds Teaching Hospitals NHS Trust, UK


The NIHR Invention for Innovation Programme: Funding Translational Research in Healthcare Technologies
Martin Hunt
, Head of the NIHR Invention for Innovation Programme (i4i), UK

  • What we fund
  • What a successful application looks like
  • How the application and review process works


The role of NIHR Office for Clinical Research Infrastructure (NOCRI) in Facilitating Links between Researchers and Industry
Ravi Chana
Business Development Manager at the NIHR Office for Clinical Research Infrastructure (NOCRI) NIHR, UK

  • The NIHR Infrastructure in general
  • NIHR Centres of Excellence in MedTech (with case studies)
  • Process for Engaging experts


Infection Research and NIHR Biomedical Research Centres

Jonathan Edgeworth, Guy’s and St Thomas’s NHS Foundation Trust, UK


Networking, Lunch Break and visit the Exhibition


Keynote Lecture: Update on Influenza Pathogenesis, Prevention and Treatment
Peter JM Openshaw, Imperial College London, UK


Session 8: Vaccines Part I
Chair: Charles Lacey, University of York, UK


The Challenges of Vaccine Clinical Trials
Matthew Snape, University of Oxford Vaccine Group, UK


Vaccine Clinical Trials from an Industry Perspective
Philip Cruz, GSK, UK

  • Overview of vaccine development
  • Industry perspectives on clinical research in trial design and site/country selection
  • Case study example


Networking, Coffee Break and visit the Exhibition


Session 8: Vaccines Part II
Chair: Charles Lacey, University of York, UK


The PERISCOPE Project: Clinical Studies to Determine Immune Correlates of Protection for Pertussis
Andrew Gorringe, 
Public Health England, UK


Live Attenuated Influenza Viruses
Richard Pebody, Centre for Infectious Disease Surveillance and Control at Public Health England, UK


Congress Closing remarks